



The Greater North Texas Pain Society and Covidien cordially invites you to attend a presentation discussing:

EXALGO™

“A once daily extended release Hydromorphone option for moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.”

Paul A. Grant Sr., MD

Tuesday, November 8, 2011

6:30 PM

Bailey's Prime Plus Steakhouse

8160 Park Lane

Dallas, TX 75231

(214) 750-8100

Please RSVP by accessing the following registration Web page:

Please contact your Covidien Sales Representative for more information:
Dina Ali (dina.ali@covidien.com) or Brynn Crow (brynn.crow@covidien.com)
RSVPs are requested by Friday, November 4th

This event is promotional; there are no certified continuing medical educational credits approved for this presentation.

Covidien proudly adheres to the Pharmaceutical Research and Manufacturers Association Code for Interactions with Healthcare Professionals. Attendance must be limited strictly to healthcare professionals. Spouses and other guests cannot be accommodated. Thank You.

Please see back side of the invitation for boxed warning.

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG. EXALGO is a registered trademark of Mallinckrodt Inc. © 2010 Mallinckrodt Inc., a Covidien company.

Mallinckrodt



**WARNING: POTENTIAL FOR ABUSE, IMPORTANCE OF PROPER PATIENT
SELECTION AND LIMITATIONS OF USE**

Potential for Abuse

EXALGO contains hydromorphone, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid analgesics. EXALGO can be abused in a manner similar to other opioid agonists, legal or illicit. These risks should be considered when administering, prescribing, or dispensing EXALGO in situations where the healthcare professional is concerned about increased risk of misuse, abuse, or diversion. Schedule II opioid substances which include hydromorphone, morphine, oxycodone, fentanyl, oxymorphone and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression [see *Drug Abuse and Dependence (9)*].

Proper Patient Selection

EXALGO is an extended-release formulation of hydromorphone hydrochloride indicated for the management of moderate to severe pain in opioid tolerant patients when a continuous around-the-clock opioid analgesic is needed for an extended period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg of oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg of oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer [see *Indications and Usage (1) and Dosage and Administration (2)*].

EXALGO is for use in opioid tolerant patients only [see *Indications and Usage (1) and Dosage and Administration (2)*].

Fatal respiratory depression could occur in patients who are not opioid tolerant.

Accidental consumption of EXALGO, especially in children, can result in a fatal overdose of hydromorphone [see *Warnings and Precautions (5.1)*].

Limitations of Use

EXALGO is not indicated for the management of acute or postoperative pain [see *Indications and Usage (1)*].

EXALGO is not intended for use as an as needed analgesic [see *Indications and Usage (1)*].

EXALGO tablets are to be swallowed whole and are not to be broken, chewed, dissolved, crushed or injected. Taking broken, chewed, dissolved or crushed EXALGO or its contents leads to rapid release and absorption of a potentially fatal dose of hydromorphone [see *Warnings and Precautions (5)*].